# Zevra Therapeutics

Type: Company (ZVRA)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/zevra-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/zevra-therapeutics

## Timeline

- **2026-03-19**: Earnings Call — Management hosts a conference call to discuss 2025 performance and 2026 outlook.
- **2026-03-18**: Financial Reporting — XOMA files Q4 and Full Year 2025 financial results with the SEC.
- **2026-02-02**: Asset Acquisition — Completion of a significant acquisition of royalty rights from a clinical-stage partner.
- **2026-01-12**: Strategic Disclosure — XOMA issues Regulation FD disclosure regarding portfolio updates.

## Recent coverage (2 stories)

### XOMA Royalty Reports Q4 Results as Portfolio Scaling Drives Long-Term Value
2026-03-19 15:43:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Full story: https://getbiobrief.com/story/xoma-royalty-q4-2025-earnings-analysis

### Zevra Therapeutics Taps Biotech Veteran Justin Renz as New CFO
2026-03-05 13:45:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.
Full story: https://getbiobrief.com/story/zevra-therapeutics-appoints-justin-renz-cfo

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.